<DOC>
	<DOCNO>NCT00197132</DOCNO>
	<brief_summary>Fluid management study patient insulin resistance .</brief_summary>
	<brief_title>Study In Patients With Insulin Resistance</brief_title>
	<detailed_description />
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>BMI 2736 kg/m2 inclusive least two additional feature metabolic syndrome first degree relative history type 2 diabetes mellitus . BMI = Weight/height² , ( weight kg , height ) . Male female age 30 65 year , inclusive , screen . Female subject must postmenopausal ( i.e . &gt; 6 month without menstrual period ) , surgically sterile , use effective contraceptive measure ( oral contraceptive , Norplant DepoProvera ) intrauterine device ( IUD ) ( diaphragm spermicide condom spermicide ) . Women childbearing potential must use effective contraceptive measure least 1 month prior visit 1 , continue use contraceptive method study 30 day discontinue study treatment . Willing able provide sign dated write informed consent . Subjects type 2 diabetes mellitus define HbA1c level &gt; 6.5 % fast plasma glucose &gt; 7.0 mmol/L . If fasting plasma glucose 6.1 7.0 mmol/L 75 g oral glucose test perform exclude diabetes mellitus . Subjects initiate lipid lower therapy within last 6 month subject increase dose therapy within last 3 month prior study start . Subjects take Non Steroidal Antiinflammatory Drugs , fibrates , anticoagulant cardiovascular medication ( βblockers , nitrate , calcium antagonist , ACE inhibitor , angiotensin II antagonist , alpha blocker , diuretic , centrally act antihypertensive , directly act antihypertensive e.g. , diazoxide , digoxin , antiarrhythmic ) unable stop medication duration study . Exposure thiazolidinedione ( TZD ) PPARγ agonist ( e.g . rosiglitazone , troglitazone , pioglitazone , G1262570 ) within last 4 month participation clinical study involve TZD PPARγ agonist . Subjects require use antidiabetic medication time . Use investigational drug within 30 day precede first dose medication start study . Subjects document history significant hypersensitivity ( e.g . difficulty swallowing , difficulty breathing , tachycardia skin reaction ) thiazolidinediones PPARγ agonist . Systolic blood pressure &gt; 160 mmHg diastolic blood pressure &gt; 100 mmHg receive antihypertensive therapy . Subjects unstable severe angina ( require continual therapy ) congestive heart failure . Presence clinically significant hepatic disease . Clinically significant anaemia . Subjects creatinine clearance &lt; 40 mL/min . Women lactate , pregnant planning become pregnant course study . Alcohol drug abuse within last 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Insulin resistance vasodilatory response</keyword>
</DOC>